共 49 条
- [21] Dual targeting of CDK4/6 and Bcl-2 exhibits a potent antitumor effect on mantle cell lymphomaBLOOD ADVANCES, 2023, 7 (14) : 3361 - 3365Che, YuxuanLiu, YangLi, YijingMcIntosh, Joseph M.Jordan, AlexaYan, FangfangWang, WeiNie, LeiLee, Heng-HuanJin, JinglingYao, YixinZhao, ZhongmingJiang, Vivian ChangyingWang, Michael
- [22] Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activityBLOOD, 2006, 108 (05) : 1744 - 1750Marzec, MichalKasprzycka, MonikaLai, RaymondGladden, Andrew B.Wlodarski, PawelTomczak, EwaNowell, PeterDePrimo, Samuel E.Sadis, SethEck, StephenSchuster, Stephen J.Diehl, J. AlanWasik, Mariusz A.
- [23] Cdk4/6 Inhibitor PD 0332991 Demonstrates Cell Cycle Inhibition Via FLT-PET Imaging and Tissue Analysis in Patients with Recurrent Mantle Cell LymphomaBLOOD, 2008, 112 (11) : 104 - 104Leonard, John P.LaCasce, AnnSmith, Mitchell R.Noy, ArielaYap, Jeffrey T.Van den Abbeele, Annick D.Yu, Jian Q.Chen-Kiang, SelinaEly, Scott A.Vallabhajosula, ShankarChirieac, Lucian R.Larson, Steven M.Shapiro, Geoffrey I.Schoder, Heiko
- [24] Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathwaysBRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (05) : 765 - 768Zhao, XiaoxianBodo, JurajSun, DanyuDurkin, LisaLin, JeffreySmith, Mitchell R.Hsi, Eric D.
- [25] CDK4/6 inhibitor-resistant ER plus breast cancer cell lines are hypersensitive to TTK inhibitionCANCER RESEARCH, 2020, 80 (04)Bretones, Isabel SoriaThu, Kelsie L.Silvester, JenniferKiarash, RezaFletcher, Graham C.Cruickshank, JenniferBray, Mark R.Mak, Tak W.Cescon, David W.
- [26] BET Protein Bromodomain Antagonist-Based Combinations Exert Synergistic Pre-Clinical Activity Against Ibrutinib-Sensitive or -Resistant Human Mantle Cell Lymphoma (MCL) CellsBLOOD, 2015, 126 (23)Sun, BaohuaFiskus, WarrenSaenz, Dyana T.Krieger, StephanieZhang, LiangParmar, SimritWang, MichaelBhalla, Kapil N.
- [27] Harnessing Btki Therapy By CDK4/6i Control of T Effector Memory Cells and T Cell Surveillance in Mantle Cell LymphomaBLOOD, 2023, 142Di Liberto, MaurizioHu, YangHuang, XiangaoInghirami, GiorgioWang, KevinLee, ChristinaMaddocks, Kami J.Blum, Kristie A.Ruan, JiaLeonard, John P.Bartlett, Nancy L.Martin, PeterElemento, OlivierChen-Kiang, Selina
- [28] Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancerMOLECULAR THERAPY, 2022, 30 (04) : 1628 - 1644Han, WantingLiu, MingyuHan, DongToure, Anthia A.Li, MuqingBesschetnova, AnnaWang, ZifengPatalano, SusanMacoska, Jill A.Lam, Hung-MingCorey, EvaHe, Housheng HansenGao, ShuaiBalk, Steven P.Cai, Changmeng
- [29] Disrupting GRINL1A Association with Cereblon Accelerates IKZF1/3 Degradation and IMiD Killing of Mantle Cell Lymphoma Cells By CDK4/6 InhibitionBLOOD, 2019, 134Zhao, NicoleDi Liberto, MaurizioElemento, OlivierChen-Kiang, SelinaHuang, Xiangao
- [30] PRMT5 Inhibition Modulates E2F1 and P53 to Restore Cell Cycle Regulation and Drive DNA Damage Response in Ibrutinib-Resistant Mantle Cell LymphomaBLOOD, 2021, 138Sloan, ShelbyBrown, FionaLong, MackenzieHelmig-Mason, JoBethBeck, StaceyChung, Ji HyunHanel, WalterBrooks, EricKlimazewski, HaleyMeydan, CemFoox, JonathanButler, DanielByrd, John C.Lapalombella, RosaDi Liberto, MaurizioMason, ChristopherChen-Kiang, SelinaVaddi, KrisScherle, PeggyBaiocchi, RobertAlinari, Lapo